Search for:
Category

Hungary

Category

Recent amendments of Act XCVIII of 2006 („Medicine Economy Act”) have significant impact on medicine and device promotion, interactions with healthcare professionals as well as the pricing and reimbursement of medicinal products. The amendments blur the distinction between promotional and professional/scientific activities and communication which will require assessment of the types of events organized and HCP engagements concluded by pharma companies.

In brief The National Institute of Pharmacy and Nutrition (“OGYÉI”) has issued new decisions on its webpage concerning pharmaceutical promotional activities and interactions with HCPs in which the commercial practices of two pharmaceutical companies were investigated and fines were imposed due to alleged infringements. The key findings of the decisions…

The National Institute of Pharmacy and Nutrition (“OGYÉI”) published new decisions on its webpage concerning pharmaceutical promotional activities and interactions with HCPs. The OGYÉI investigated the commercial practices of Aramis Pharma Kft., Lilly Hungária Kft. and Sager Pharma Kft. and imposed fines due to alleged infringements.

Just a few days after the entry into force of the special tax on retailers (effective as of 1 May 2020), which may amount to as much as 2.5% of their annual turnover, the Hungarian Government further tightened the rules on the distribution of food products by significantly restricting  traders’ freedom to negotiate purchase prices.

The financial markets are experiencing a significant amount of disruption for which there is no precedent. However, in these difficult times it is important that originators, sponsors and securitisation special purpose entities (SSPEs) do not lose sight of their regulatory obligations under Regulation (EU) 2017/2402 (Securitisation Regulation). This short briefing…